Clinical Trial Update: BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing BAY79-4980 with recombinant FVIII-FS in previously treated patients with severe Hemophilia A was terminated, with results posted in Au…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY79-4980
• rFVIII-FS (recombinant factor VIII-FS)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 2 | Status: TERMINATED | Results posted: 2011-08-17